Akums Drugs & Pharmaceuticals Ltd: Valuation Shifts Signal Changing Price Attractiveness

Valuation Metrics: From Attractive to Fair

Akums Drugs currently trades at a P/E ratio of 41.25, a figure that has increased relative to its historical levels, signalling a shift from very attractive to fair valuation territory. This P/E is slightly higher than some of its direct competitors such as Ajanta Pharma (39.75) and Gland Pharma (39.12), but remains below the very expensive valuations seen in companies like Wockhardt (98.11) and Rubicon Research (95.85). The company’s price-to-book value (P/BV) stands at 3.35, which is moderate within the pharmaceuticals sector, indicating that the market is pricing in reasonable growth expectations without excessive premium.

Other valuation multiples further contextualise Akums’ standing. The enterprise value to EBITDA (EV/EBITDA) ratio is 18.32, which is lower than several peers such as Ajanta Pharma (29.8) and J B Chemicals (34.71), suggesting comparatively better operational earnings relative to enterprise value. The EV to EBIT multiple of 26.03 also reflects a balanced valuation, neither deeply discounted nor overly stretched.

Financial Performance and Quality Metrics

Akums’ return on capital employed (ROCE) is a healthy 20.53%, underscoring efficient use of capital to generate earnings. However, the return on equity (ROE) is more modest at 8.11%, which may reflect capital structure or profitability nuances. The dividend yield remains low at 0.43%, consistent with a growth-oriented pharmaceutical company reinvesting earnings for expansion.

Stock Price Movement and Market Capitalisation

The stock price of Akums Drugs has surged 6.63% on the day, closing at ₹701.65, just shy of its 52-week high of ₹707.00. This recent rally is part of a broader upward trend, with the stock delivering a remarkable 54.65% return year-to-date, vastly outperforming the Sensex, which has declined 8.98% over the same period. Over the past month, the stock gained 18.45%, while the benchmark index rose a modest 4.85%. This strong relative performance highlights investor confidence in Akums’ growth prospects despite the valuation adjustment.

Comparative Valuation: Peers and Sector Context

When compared with its pharmaceutical and biotechnology peers, Akums Drugs’ valuation appears more reasonable. Several companies in the sector are trading at very expensive multiples, with P/E ratios exceeding 50 in some cases, such as J B Chemicals & Pharmaceuticals at 53.87 and Sai Life Sciences at 75.67. Even the EV/EBITDA multiples for these companies are significantly higher, often surpassing 40, indicating stretched valuations.

In contrast, Akums’ PEG ratio is reported as zero, which may indicate either a lack of consensus on earnings growth estimates or a data anomaly. Nonetheless, this metric suggests that the stock is not currently priced for excessive growth expectations, aligning with its fair valuation grade. This contrasts with peers like Ajanta Pharma, which has a PEG of 2.7, implying a higher premium for growth.

Investment Grade and Market Capitalisation

MarketsMOJO has upgraded Akums Drugs’ Mojo Grade from Sell to Hold as of 10 April 2026, reflecting improved sentiment and valuation comfort. The company holds a Mojo Score of 62.0, indicating moderate favourability based on multiple parameters including financial health, valuation, and momentum. Classified as a small-cap stock, Akums offers investors exposure to a growing pharmaceutical player with a balanced risk-reward profile.

Return Analysis Versus Sensex Benchmarks

Akums Drugs’ stock has outperformed the Sensex across multiple time frames. Over one week, the stock gained 12.05% compared to a slight 0.25% decline in the Sensex. Over one year, Akums delivered a 27.34% return while the Sensex fell 6.76%. This outperformance underscores the company’s resilience and growth potential amid broader market volatility. The stock’s 52-week low of ₹410.10 to a high near ₹707.00 reflects strong upward momentum and investor appetite.

Implications for Investors

The shift in Akums Drugs’ valuation from very attractive to fair suggests that much of the company’s growth potential has been recognised by the market. While the stock no longer trades at a deep discount, its valuation remains reasonable relative to peers, especially given its strong operational metrics and robust returns. Investors should weigh the company’s solid ROCE of 20.53% and improving market sentiment against the elevated P/E ratio and modest ROE.

Given the recent upgrade in Mojo Grade to Hold, the stock may be suitable for investors seeking exposure to the pharmaceuticals sector with a balanced risk profile. However, the relatively high P/E and EV multiples imply that further price appreciation may depend on continued earnings growth and operational execution.

Conclusion

Akums Drugs & Pharmaceuticals Ltd has transitioned into a fair valuation zone after a period of very attractive pricing, reflecting the market’s recognition of its growth trajectory. The company’s strong stock performance, outpacing the Sensex and many peers, highlights investor confidence. While valuation multiples have expanded, they remain moderate compared to several very expensive sector players. The recent upgrade to a Hold rating by MarketsMOJO further supports a cautious but optimistic outlook. Investors should monitor earnings trends and sector dynamics closely to assess the stock’s future potential within the pharmaceuticals and biotechnology space.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →